<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434291</url>
  </required_header>
  <id_info>
    <org_study_id>TG-873870-02</org_study_id>
    <nct_id>NCT00434291</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia</brief_title>
  <official_title>A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This study will test the safety and efficacy of TG-873870(Nemonoxacin) compared with
      Levofloxacin in adult patients with Community-Aquired Pneumonia(CAP)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Community-acquired Pneumonia(CAP) remains a leading cause of death in both developing and
      developed countries. In the choice of antibacterial agents used to treat CAP,
      fluoroquinolones have received considerable attention because of their wide spectrum of
      bactericidal activity. TG-873870(Nemonoxacin), a non-fluorinated quinolone (NFQ), is a
      selective bacterial topoisomerase inhibitor. This study will test the safety and efficacy of
      TG-873870(Nemonoxacin) compared with Levofloxacin in adult patients with Community-Aquired
      Pneumonia (CAP) .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Cure Rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacteriologic Cure Rate</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Community-Acquired Pneumonia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-873870(Nemonoxacin)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If female, non-lactating and at no risk or pregnancy (post-menopausal or must use
             adequate birth control)

          -  Must be a suitable candidate for oral antibiotic therapy and must be able to swallow
             capsules intact

          -  Must have a clinical diagnosis of CAP based on clinical evidence

          -  Must have a chest radiograph demonstrating new or persistent/progressive infiltrates

          -  Must be able to produce sputum

        Exclusion Criteria:

          -  Clinically significant conduction or other abnormality on 12-lead ECG, or QTc interval

          -  Patients with CAP that, in the investigator's judgment, is severe enough to require
             hospitalization for intravenous antibiotic therapy and/or supplemental oxygen therapy
             with ICU support

          -  Known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary
             tuberculosis or infection with other mycobacteria or fungi, known bronchial
             obstruction, a history of post-obstructive pneumonia, other confounding respiratory
             diseases, such as lung cancer, malignancy metastatic to the lungs, lung abscess,
             empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory
             infection (chronic obstructive pulmonary disease [COPD] is not exclusionary)

          -  Infection acquired in a hospital, nursing home, or other long-term care facility, or
             hospitalization for any reason within the previous 14 days

          -  Treatment with any antibiotics within the past 7 days prior to randomization, unless
             documents to be a treatment failure(72 hours treatment and not responding)

          -  Anticipation of the requirement for additional treatment with non-study antibacterials
             for any reason during the patient's participation in the study

          -  Treatment with chemotherapeutic agents or oncolytics during the 6 months prior to
             randomization or anticipated requirement for such agents during the course of the
             study

          -  Known or suspected CNS disorder that may predispose the patient to seizures or lower
             the seizure threshold
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reury-Perng Perng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming-Lin Ho, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang-Hua Christian Hospital, Changhua, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wann-Cherng Perng, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kai-Ming Chang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital, Taichung, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yen-Hsu Chen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaoshiung Medical University Hospital, Kaoshiung, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ren-Guang Wu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cheng Ching Hospital, Taichung, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yin-Ching Chuang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chi-Mei Foundation Hospital, Tainan, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Horng-Chyuan Lin, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang-Gung Memorial Hospital, Taoyuan, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yao-Kuang Wu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Taipei Tzu Chi General Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hsi-Hsun Lin, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>E-Da Hospital, Kaohsiung, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AJ Bester, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>GCT at Jubilee Hospital, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Breedt, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bougainville Hospital, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CT de Villiers, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>de Villers Clinical Trials, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Gani, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>GCT Trial Centre, Mercantile Hospital, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Y Kelfkens, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DJ Jansen van Rensburg, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Park Medical Centre, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Jurgens, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>DJW Research, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>IH Mitha, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benmed/Pentagon Hospital, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JH Mynhardt, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G Nieuwoudt, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>MediTrials, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J Kasumba, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>JOSHA Research, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E van Nieuwenhuizen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastmed Clinical Trial Center, RSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CJJ van Rensburg, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private, RSA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GCT at Jubilee Hospital</name>
      <address>
        <city>Temba</city>
        <state>North West</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benmed/Pentagon Hospital</name>
      <address>
        <city>Benomi</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediTrials</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private</name>
      <address>
        <city>Kimberley</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJW Research</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCT Trial Centre, Mercantile Hospital</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private</name>
      <address>
        <city>Potchefstroom</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bougainville Hospital</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>de Villers Clinical Trials</name>
      <address>
        <city>Scottburgh</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Medical Centre</name>
      <address>
        <city>Witbank</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Hua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaoshiung Medical University Hospital</name>
      <address>
        <city>Kaoshiung</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Ching Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Foundation Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhist Taipei Tzu Chi General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/</url>
    <description>NCBI</description>
  </link>
  <reference>
    <citation>Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis. 1998 Apr;26(4):811-38.</citation>
    <PMID>9564457</PMID>
  </reference>
  <reference>
    <citation>Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C; Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003 Dec 1;37(11):1405-33. Epub 2003 Nov 3.</citation>
    <PMID>14614663</PMID>
  </reference>
  <reference>
    <citation>Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000 Aug;31(2):347-82. Epub 2000 Sep 7.</citation>
    <PMID>10987697</PMID>
  </reference>
  <reference>
    <citation>Fujimoto T, Mitsuhashi S. In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin. Chemotherapy. 1990;36(4):268-76.</citation>
    <PMID>2174762</PMID>
  </reference>
  <reference>
    <citation>Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63(24):2769-802. Review.</citation>
    <PMID>14664657</PMID>
  </reference>
  <reference>
    <citation>Ellner PD, Neu HC. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA. 1981 Oct 2;246(14):1575-8.</citation>
    <PMID>7277631</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2007</study_first_submitted>
  <study_first_submitted_qc>February 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2007</study_first_posted>
  <last_update_submitted>November 23, 2009</last_update_submitted>
  <last_update_submitted_qc>November 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <keyword>Community-acquired Pneumonia</keyword>
  <keyword>fluoroquinolone</keyword>
  <keyword>TG-873870</keyword>
  <keyword>Nemonoxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

